Core Platform
Proprietary Platform Technology & Diversified Pipeline
At the core of MediWound’s innovation is a proprietary platform based on a unique mixture of proteolytic enzymes, enriched in bromelain— derived from the stem of the pineapple plant. Using our exclusive enzyme enrichment technology, these bioactive compounds are carefully extracted, purified, and enhanced to achieve maximum therapeutic potential.
This platform serves as the foundation for both our approved product and our entire pipeline of biologic therapies in development. With multiple mechanisms of action, bromelain offers broad clinical applicability across various therapeutic areas.
Our mission is to lead a shift toward non-surgical solutions that redefine standards of care, with a current focus on therapies that promote and accelerate tissue repair.
When topically applied to burns or wounds, the enzymes selectively break down non-viable tissue while leaving healthy, viable tissue unharmed.
Plant to Drug
MediWound’s proprietary process is designed to preserve and amplify the natural efficacy of bromelain—from plant harvest to final pharmaceutical product—ensuring consistency, potency, and reliability at every stage.
Publications
NexoBrid®
Clinical Guidelines
Clinical studies
Review
Rosenberg L, Shoham Y, Krieger Y, Rubin G, Sander F, Koller J, David K, Egosi D, Ahuja R, ...
Minimally invasive burn care: a review of seven clinical studies of rapid and selective debridement ...
Major clinical benefits
Face Burns
Schulz A, Fuchs PC, Rothermundt I, Hoffmann A, Rosenberg L, Shoham Y, Oberländer H, Schief...
Enzymatic debridement of deeply burned faces: Healing and early scarring based on tissue preservatio...
Cost – effectiveness
Cost Saving compared to SOC
Minic J, Vestita M, Vigato E, Dallapozza E, Shoham Y, Lavagnolo U, Bianchi FP, Fratucello ...
Economic analysis of enzymatic debridement versus standard burn care: a retrospective analysis. Ann ...
Unmet need
Tangential excision compromise healthy tissue
Gurfinkel R, Rosenberg L, Cohen S, Cohen A, Barezovsky A, Cagnano E, Singer AJ.
Histological assessment of tangentially excised burn eschars. Can J Plast Surg. 2010 Fall;18(3):e33-...
Market Experience
>10 years of experience
Shoham Y, Gasteratos K, Singer AJ, Krieger Y, Silberstein E, Goverman J.
Bromelain-based enzymatic burn debridement: A systematic review of clinical studies on patient safet...
Clinical studies
DETECT study
Shoham Y, Rosenberg L, Hickerson W, Goverman J, Iyer N, Barrera-Oro J, et al.
Early enzymatic burn debridement: results of the DETECT multicenter randomized controlled trial. J B...
Major clinical benefits
Preventing Burn induced compartment Syndrome
Krieger Y, Rosenberg L, Lapid O, Glesinger R, Bogdanov-Berezovsky A, Silberstein E, Sagi A...
Escharotomy with an enzymatic debridement agent for treating experimental burn-induced compartment s...
Clinical Guidelines
WHO BMCI guidelines
World Health Organization. WHO guidelines for burn wound care. Geneva: World Health Organization; 20...
Major clinical benefits
Hand Burns
Malsagova AT, El-Habbassi A, Billner M, Berns M, Pueski T, Bodenschatz KJ, Heidekrueger PI...
Long-term functional outcomes following enzymatic debridement of deep hand burns using Nexobrid®: a ...
Clinical studies
Pediatric study
Shoham Y, Rosenberg L, Narayan RP, Staubach R, Bene R, Kakola M, Monstrey SJ, Wilson Y, Ma...
Open label RCT of the efficacy and safety of NexoBrid compared to SOC in children with burns. Burns....
Clinical Guidelines
Clinical Guidelines
WHO BMCI guidelines
World Health Organization.
WHO guidelines for burn wound care. Geneva: World Health Organization; 2022.
Unmet need
Time to start putting down the knife
Edmondson SJ, Jumabhoy IA, Murray A.
Time to start putting down the knife: A systematic review of burns excision tools of randomised and ...
Clinical Guidelines
European consensus guidelines update (2020)
Hirche C, Kreken Almeland S, Dheansa B, Fuchs P, Governa M, Hoeksema H, Korzeniowski T, Lu...
Eschar removal by bromelain-based enzymatic debridement (Nexobrid®) in burns: European consensus gui...
Clinical studies
EU study
Rosenberg L, Krieger Y, Bogdanov-Berezovski A, Silberstein E, Shoham Y, Singer AJ.
A novel rapid and selective enzymatic debridement agent for burn wound management: a multi-center RC...
Major clinical benefits
Genital burns
Schulz A, Ribitsch B, Fuchs PC, Lipensky A, Schiefer JL.
Treatment of genital burn injuries: traditional procedures and new techniques. Adv Skin Wound Care. ...
EscharEx®
Pre-Clinical
Comparison to SANTYL
Shoham Y, Sabbag I, Singer AJ.
Development of a porcine hard-to-heal wound model: evaluation of a bromelain-based enzymatic debridi...
Mechanism of action
Effect on Biofilm
Watters CM, Burton T, Kirui DK, Millenbaugh NJ.
Enzymatic degradation of in vitro Staphylococcus aureus biofilms supplemented with human plasma. Inf...
Mechanism of action
Mechanism of Action
Snyder RJ, deLancey Pulcini E, Rosenberg L, Shoham Y.
Bromelain-based enzymatic debridement: mechanism of action in the wound environment. A literature re...
Clinical studies
Post hoc analysis vs. SANTYL
Dove CY, Snyder RJ, Zarbiv KD, Katz-Levy Y, Klinger E, Haviv A, Shoham Y, Sigal F.
Bromelain versus collagenase-based debridement in venous leg ulcers: post-hoc analysis of ChronEx Tr...
Clinical studies
Preliminary results with NexoBrid in chronic ...
Shoham Y, Krieger Y, Tamir E, Silberstein E, Bogdanov-Berezovsky A, Haik J, Rosenberg L.
Bromelain-based enzymatic debridement of chronic wounds: A preliminary report. Int Wound J. 2018 Oct...
Clinical studies
PharmEx study results
Snyder RJ, Singer AJ, Dove CR, Heisler S, Petusevsky H, James G, deLancey Pulcini E, Ben Y...
An open-label, proof-of-concept study assessing the effects of bromelain-based enzymatic debridement...
Clinical studies
MW - 2013 study results in VLU, DFU and Traum...
Shoham Y, Shapira E, Haik J, Harats M, Egozi D, Robinson D, Kogan L, Elkhatib R, Telek G, ...
Bromelain-based enzymatic debridement of chronic wounds: Results of a multicentre randomized control...
Clinical studies
ChronEx study results (eClinicalMedicine of t...
Kirsner RS, Bohn G, Driver VR, Serena TE, Snyder RJ, Eaglstein WH, et al.
Safety and efficacy of a bromelain-based enzymatic debridement agent for venous leg ulcers: a random...